Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia"

Comments

Dalian Women and Children's Medical Group Dalian

Haematologica Early view Jul 23, 2026 https://doi.org/10.3324/haematol.2026.301608

Abstract

Not available.

Early view : Comments

DOI

Published

2026-07-23

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Copyright & Usage

Online Views

64

PDF Downloads

53

No Data

PlumX